About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Oruka Therapeutics, Inc. (ORKA): Insider Trades and Fund Holdings
In the past 12 months, Oruka Therapeutics, Inc. insiders reported no open-market purchases and 17 sales worth $22.0M; 14 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.
- Oct 20, 2026Insider saleGeneral Counsel Paul T. Quinlan sold $706,735 under a 10b5-1 plan
- Oct 15, 2026Insider saleChief Medical Officer Joana Goncalves sold $523,648 under a 10b5-1 plan
- Oct 15, 2026Planned saleJOANA GONCALVES (officer) filed notice to sell about $1.6 million around Oct 15, 2026
- Oct 13, 2026Planned saleArjun Agarwal (officer) filed notice to sell about $821,018 around Oct 12, 2026
- Oct 12, 2026Insider salePresident Arjun Agarwal sold $805,888 under a 10b5-1 plan
- Oct 1, 2026Insider saleCEO Lawrence Otto Klein sold $2.1 million under a 10b5-1 plan
- Oct 1, 2026Planned saleLAWRENCE KLEIN (director, officer) filed notice to sell about $2.1 million around Oct 1, 2026
- Sep 21, 2026Insider saleGeneral Counsel Paul T. Quinlan sold $936,418 under a 10b5-1 plan
- Sep 21, 2026Insider salePresident Arjun Agarwal sold $51,035 under a 10b5-1 plan
- Sep 21, 2026Planned saleArjun Agarwal (officer) filed notice to sell about $50,614 around Sep 21, 2026
- Sep 15, 2026Insider saleChief Medical Officer Joana Goncalves sold $734,145 under a 10b5-1 plan
- Sep 15, 2026Insider saleCEO Lawrence Otto Klein sold $234,681
- Sep 15, 2026Insider saleGeneral Counsel Paul T. Quinlan sold $99,443
- Sep 15, 2026Insider saleCOO Laura Lee Sandler sold $86,713
- Sep 15, 2026Insider salePresident Arjun Agarwal sold $53,598 under a 10b5-1 plan
- Sep 11, 2026Insider salePresident Arjun Agarwal sold $872,413 under a 10b5-1 plan
- Sep 1, 2026Insider saleCEO Lawrence Otto Klein sold $6.9 million under a 10b5-1 plan (8 days after: executive or director change)
- Sep 1, 2026Insider saleCOO Laura Lee Sandler sold $459,102 under a 10b5-1 plan (8 days after: executive or director change)
- Sep 1, 2026Planned saleLAWRENCE KLEIN (director, officer) filed notice to sell about $6.9 million around Sep 1, 2026
- Sep 1, 2026Planned saleLAURA SANDLER (officer) filed notice to sell about $463,100 around Sep 1, 2026
- Aug 24, 2026NewsCompany reported: Executive or director change
- Aug 17, 2026Insider saleChief Medical Officer Joana Goncalves sold $782,882 under a 10b5-1 plan
- Aug 14, 2026Insider saleGeneral Counsel Paul T. Quinlan sold $5.6 million under a 10b5-1 plan
- Aug 13, 2026Insider salePresident Arjun Agarwal sold $1.1 million under a 10b5-1 plan
- Jun 30, 2026FundViking Global Investors cut 44% in Q2 2026 (13F filed Aug 14, 2026)
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 20, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 20 | Paul T. QuinlanGeneral Counsel | ▼ SELL10b5-1 | $707K |
| Oct 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $524K |
| Oct 13 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $806K |
| Oct 2 | Lawrence Otto KleinCEO | ▼ SELL10b5-1 | $2.09M |
| Sep 21 | Paul T. QuinlanGeneral Counsel | ▼ SELL10b5-1 | $936K |
| Sep 21 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $51K |
| Sep 15 | Arjun AgarwalPresident | ▼ SELL10b5-1 | $872K |
| Sep 15 | Joana GoncalvesChief Medical Officer | ▼ SELL10b5-1 | $734K |
| Sep 15 | Lawrence Otto KleinCEO | ▼ SELL | $235K |
| Sep 15 | Paul T. QuinlanGeneral Counsel | ▼ SELL | $99K |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Paul T. Quinlan | General Counsel | 0 | $0 | 4 | $7.38M |
| Joana Goncalves | Chief Medical Officer | 0 | $0 | 3 | $2.04M |
| Arjun Agarwal | President | 0 | $0 | 5 | $2.85M |
| Lawrence Otto Klein | CEO | 0 | $0 | 3 | $9.21M |
| Laura Lee Sandler | COO | 0 | $0 | 2 | $546K |
Tracked funds that report ORKA
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Viking Global Investors | 1,503,478 | $143.1M | ▼ −43.6% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →